TCIM
NBSE

TIAA CREF Investment Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

TIAA CREF Investment Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-135
Closed -$136K – 3155
2015
Q2 		$136K Sell
135
-47
-26% -$50.7K ﹤0.01% 3139
2015
Q1 		$185K Hold
182
– – ﹤0.01% 3064
2014
Q4 		$607K Sell
182
-16
-8% -$49.1K ﹤0.01% 2901
2014
Q3 		$574K Buy
198
+2
+1% +$6.62K ﹤0.01% 2916
2014
Q2 		$744K Buy
+196
New +$738K ﹤0.01% 2887

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
HF
Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

TIAA CREF Investment Management's NBSE Position: Q3 2015 in Review

TIAA CREF Investment Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2015, closing a stake of 135 shares — an estimated $136K sold.

TIAA CREF Investment Management first reported a position in NBSE in Q2 2014 and held it in 5 quarters. The position peaked at $744K in Q2 2014. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2015.

  • TIAA CREF Investment Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • TIAA CREF Investment Management sold 135 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $136K.
  • TIAA CREF Investment Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 5 quarters.
  • TIAA CREF Investment Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $744K in Q2 2014.
  • 47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2015.

Based on TIAA CREF Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.